IrishMc67 (@IrishMc67) profile picture
Joined September 2023
Photo by IrishMc67 (@IrishMc67)Photo by IrishMc67 (@IrishMc67)Photo by IrishMc67 (@IrishMc67)Photo by IrishMc67 (@IrishMc67)Photo by IrishMc67 (@IrishMc67)Photo by IrishMc67 (@IrishMc67)
$NWBO #HIV #DCVax #DendriticCells #Immunotherapy ๐—ง๐—ต๐—ฒ ๐—ด๐—ผ๐—ฎ๐—น ๐—ถ๐˜€ ๐˜๐—ผ ๐—ฒ๐—ป๐—ฑ ๐˜๐—ฟ๐—ฒ๐—ฎ๐˜๐—บ๐—ฒ๐—ป๐˜ ๐˜„๐—ถ๐˜๐—ต๐—ผ๐˜‚๐˜ ๐—น๐—ผ๐˜€๐—ถ๐—ป๐—ด ๐—ฐ๐—ผ๐—ป๐˜๐—ฟ๐—ผ๐—น ๐—ผ๐—ณ ๐—›๐—œ๐—ฉ. HIV medicines suppress the virus. Silent infected cells can remain behind and restart it when treatment stops. Kalinski and Mailliardโ€™s type 1 dendritic-cell approach, called ฮฑDC1, addresses that hidden infection through the immune systemโ€™s own instructors. ๐—˜๐˜…๐—ฝ๐—ผ๐˜€๐—ฒ ๐˜๐—ต๐—ฒ ๐—ถ๐—ป๐—ณ๐—ฒ๐—ฐ๐˜๐—ถ๐—ผ๐—ป. ๐—ฃ๐—ฟ๐—ฒ๐—ฝ๐—ฎ๐—ฟ๐—ฒ ๐˜๐—ต๐—ฒ ๐—ฎ๐˜๐˜๐—ฎ๐—ฐ๐—ธ. ๐— ๐—ฎ๐—ธ๐—ฒ ๐—ฐ๐—ผ๐—ป๐˜๐—ฟ๐—ผ๐—น ๐—น๐—ฎ๐˜€๐˜. In patient-derived laboratory cultures, prepared dendritic cells helped bring latent HIV into view. In separate experiments, dendritic cells presenting HIV fragments generated killer T cells that attacked infected targets and suppressed infectious viral outgrowth. Those are real biological components of an HIV-cure strategy. Lasting control in people is the clinical goal. The new JCI Insight paper takes the next question inside the vaccine: which cells supply its strong immune instruction, and how can that function be made more consistent? The ฮฑDC1 preparation produced substantially more active IL-12 than the PGE2-matured comparator. The small percentage of cells detected making IL-12 is a laboratory measurement of one function, not a patient response rate. ๐—ง๐—ต๐—ฒ ๐—ฎ๐—ถ๐—บ ๐—ถ๐˜€ ๐—ฑ๐—ฒ๐—ฝ๐—ฒ๐—ป๐—ฑ๐—ฎ๐—ฏ๐—น๐—ฒ ๐—ฝ๐—ผ๐˜๐—ฒ๐—ป๐—ฐ๐˜†, ๐—ฏ๐—ฎ๐˜๐—ฐ๐—ต ๐—ฎ๐—ณ๐˜๐—ฒ๐—ฟ ๐—ฏ๐—ฎ๐˜๐—ฐ๐—ต. That is where Northwestโ€™s Kalinski-related licenses and ฮฑDC1 manufacturing work matter. The company is building the production and clinical-development capabilities needed to turn these cell designs into reproducible medicines. The full article connects the HIV findings, helper-cell licensing, IL-7 support and Northwestโ€™s manufacturing role around that single purpose: immune control that outlasts treatment. ๐—™๐˜‚๐—น๐—น ๐—ฎ๐—ฟ๐˜๐—ถ๐—ฐ๐—น๐—ฒ โ†“ teapawt.net/andrewcaravello/articlโ€ฆ
$NWBO Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset insight.jci.org/articles/vieโ€ฆ This paper compares two types of DC vaccine: ฮฑDC1 and PGE2-DC (pgDC). Dr. Kalinski is one of the authors. Hereโ€™s the really interesting part. Both vaccines were also tested head-to-head in a clinical trial โ€” not in cancer, but in HIV (DC-HIV04, NCT03758625). So if you think DC vaccines can only treat cancer, think again. Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (DC-HIV04) clinicaltrials.gov/study/NCTโ€ฆ Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure reporter.nih.gov/search/y6Buโ€ฆ Autologous Dendritic Cell Vaccine in HIV1 Infection clinicaltrials.gov/study/NCTโ€ฆ
7
1
32
1,132
โ€œSoonโ€ #MHRA will approve #DCVax. Approval will rewrite the oncology playbook, reset safety & efficacy bars while eroding billions in pipeline value across big pharma. Eyes on the horizon. $nwbo
$NWBO The current situation of NWBO being short raided by market makers trading in dark pools. Very well described in a Picasso painting and a supporting danish quote. Nร…R KRYBBEN ER TOM BIDES HESTENE They want real shares instead of the artificial garbage theyโ€™ve made themselves. Itโ€™s now bagholding becomes a disciplinary act of faith.
8
37
6
150
8,148
$NWBO #DCVax The closest treatment the world has ever known for the cure for cancer and it's trading below $0.14. The manipulation is criminal. People dying and the focus is purely on dollars. Unreal. @DrOzCMS @mcuban @joerogan @billmaher @MHRAgovuk @SecKennedy @realDonaldTrump
1
13
64
1,121
Replying to @MAHA_Action
#RareDisease #DIPG #DCVaxForBraelyn #GBM One in ten children. Ten thousand rare diseases. Five percent have a treatment. That five percent is the FDA's own number, printed in the notice that opened its Rare Disease Framework docket last month. ๐——๐—œ๐—ฃ๐—š ๐—ถ๐˜€ ๐—ถ๐—ป ๐˜๐—ต๐—ฒ ๐—ผ๐˜๐—ต๐—ฒ๐—ฟ ๐—ป๐—ถ๐—ป๐—ฒ๐˜๐˜† ๐—ณ๐—ถ๐˜ƒ๐—ฒ. Six years to diagnose? Not here. One MRI. Weeks, not years. ๐—ง๐—ต๐—ฒ๐˜€๐—ฒ ๐—ฐ๐—ต๐—ถ๐—น๐—ฑ๐—ฟ๐—ฒ๐—ป ๐—ฎ๐—ฟ๐—ฒ ๐—ฐ๐—ฎ๐˜‚๐—ด๐—ต๐˜ ๐—ฒ๐—ฎ๐—ฟ๐—น๐˜† ๐—ฎ๐—ป๐—ฑ ๐—ฑ๐—ถ๐—ฒ ๐—ฎ๐—ป๐˜†๐˜„๐—ฎ๐˜†. Most are past five. They die between five and ten instead, usually within a year of the scan. Fewer than one in ten lives two years. They are not lost to an incapacity to diagnose. They are lost after it. Steroids for the swelling. Radiation for a few months. Treating symptoms is exactly what they already get, and it is the ceiling. #๐——๐—–๐—ฉ๐—ฎ๐˜… ๐—ถ๐˜€ ๐˜๐—ต๐—ฒ ๐˜€๐—ฎ๐—บ๐—ฒ ๐—ฝ๐—ฟ๐—ถ๐—ป๐—ฐ๐—ถ๐—ฝ๐—น๐—ฒ. The patient's own dendritic cells, loaded with the patient's own tumor. Built for adults with resected glioblastoma. A child's brainstem cannot be resected, so the tissue has to be grown first. That step works. Tumor from 17 of 18 DIPG biopsies has been grown in culture. At UCLA, one vaccinated child was still being treated thirteen months on, from material already in storage. ๐—ง๐—ต๐—ฒ ๐—ฑ๐—ผ๐—ฐ๐—ธ๐—ฒ๐˜ ๐—ถ๐˜€ ๐—ผ๐—ฝ๐—ฒ๐—ป ๐—ฟ๐—ถ๐—ด๐—ต๐˜ ๐—ป๐—ผ๐˜„. FDA-2026-N-12214. Comments close December 11. The proposal is already in it. Add yours. ๐—ง๐—ฟ๐—ฒ๐—ฎ๐˜ ๐˜๐—ต๐—ฒ ๐—ฐ๐—ต๐—ถ๐—น๐—ฑ๐—ฟ๐—ฒ๐—ป.
$NWBO #DCVax #RareCancer FDAโ€™s Rare Disease Framework is an opportunity for DCVax-L and DCVax-Direct. ๐—•๐—ฟ๐—ถ๐—ป๐—ด ๐—ฏ๐—ผ๐˜๐—ต ๐—ฝ๐—ฟ๐—ผ๐—ด๐—ฟ๐—ฎ๐—บ๐˜€ ๐—ณ๐—ผ๐—ฟ๐˜„๐—ฎ๐—ฟ๐—ฑ. The complete evidence, practical FDA steps and companion video:
1
11
1
26
21,312
$NWBO #DCVax @DrOzCMS @SecKennedy @Siobhain_Mc @MHRAgovuk Do the right thing and get this life-saving treatment approved now! GBM patients cannot wait!!
I got the DCVax in 2015 @UCLAStrokeNSG by one of its creators Dr. Linda Liau after the grim diagnosis of a Glioblastoma Multiforme. Iโ€™ve thrived for over 11 & a half years. NO TUMOR RECURRENCE!!! How many times do I have to tell my story, it feels like Iโ€™m screaming into an echo chamber. F.F.S it works. @LisainNJUSA @kshaughnessy2 @DCVaxDefender @HollensbeAmanda @peter_brit @TheLastWord @LastWeekTonight
8
47
1,012
$NWBO #DCVax The current stock price has no basis in reality. Know what you hold!! "Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble." Warren Buffett
3
2
50
1,122
$NWBO #DCVax #GBM #SFDA ๐—ข๐—ป๐—ฒ ๐—ฃ๐—ฟ๐—ผ๐—ฑ๐˜‚๐—ฐ๐˜ ๐—Ÿ๐—ฒ๐—ณ๐˜ ๐—ฆ๐˜๐—ฎ๐—ป๐—ฑ๐—ถ๐—ป๐—ด London and Riyadh signed a regulatory agreement this week. It covers rare disease treatments and advanced therapies. It names no product. It does not need to. Line up the evidence and one product is left. ๐Ÿญ. ๐—ง๐—ต๐—ฒ ๐—ฏ๐—ฟ๐—ถ๐—ฑ๐—ด๐—ฒ Nov 16 and 17: the heads of the MHRA and the Saudi Food and Drug Authority sign a memorandum of understanding in London. Scope: rare disease treatments, advanced therapies, biotechnology products. Working clauses: product assessment, GMP, product testing, supply chain monitoring. Stated aim: patients with limited therapeutic options. ๐Ÿฎ. ๐—ช๐—ต๐—ผ ๐—ป๐—ฒ๐—ฒ๐—ฑ๐˜€ ๐—ฎ ๐—ฏ๐—ฟ๐—ถ๐—ฑ๐—ด๐—ฒ Saudi reliance pathways recognize the FDA and the EMA. Not the MHRA. They exclude advanced therapies outright. A product the FDA or EMA has approved does not need London to vouch for it. An MHRA-only cell therapy does. ๐Ÿฏ. ๐—ง๐—ต๐—ฒ ๐—ฒ๐—น๐—ถ๐—บ๐—ถ๐—ป๐—ฎ๐˜๐—ถ๐—ผ๐—ป Casgevy: approved in Saudi Arabia since January 2024. Lyfgenia and Zynteglo: FDA-approved, licensed to SPIMACO. No UK leg. Multikine: Saudi Breakthrough route plus a US trial. No UK filing announced. Fayuvi: the FDA approved it before the MHRA took the file. MeiraGTx's LCA4 gene therapy: MHRA-first by plan, no Saudi partner announced. mRNA cancer vaccines: one Phase 3 win, in melanoma. Unproven in cold tumors, and the MHRA's own rare disease draft sets them apart. ๐Ÿฐ. ๐—ง๐—ต๐—ฒ ๐˜€๐˜‚๐—ฟ๐˜ƒ๐—ถ๐˜ƒ๐—ผ๐—ฟ DCVax-L. A rare cancer. A living cell therapy made one patient at a time. The MHRA its only regulator since December 2023. Phase 3 in JAMA Oncology: 13 percent of newly diagnosed patients alive at five years, against 5.7 percent in external controls. ๐Ÿฑ. ๐—ง๐—ต๐—ฒ ๐—ฐ๐—น๐—ฎ๐˜‚๐˜€๐—ฒ๐˜€ ๐—ณ๐—ถ๐˜ GMP: the Sawston plant has held an MHRA commercial manufacturing license since 2023, one that allows export worldwide. Supply chain: NHS Blood and Transplant joined cell collection and processing in October. Assessment: one dossier, one regulator, in London. ๐Ÿฒ. ๐—ง๐—ต๐—ฒ ๐—ฆ๐—ฎ๐˜‚๐—ฑ๐—ถ ๐˜€๐—ถ๐—ฑ๐—ฒ Aug 5: the Saudi FDA issues a rare disease accelerator. It takes products through Phase 3 that are not yet registered in the Kingdom. It accepts natural history data as an external comparator when a concurrent control is not feasible. The UK is on its list of countries whose GMP certificates and inspection reports it accepts. Aug 6: Northwest Bio and SPIMACO announce an MOU that would give SPIMACO the Saudi FDA filing. SPIMACO has a dedicated unit for biological, gene and cell therapies. Saudi Breakthrough status is open only to products not yet registered with any regulator. A request has to go in before London rules, not after. At the London summit, the Saudi FDA chief called for faster access to innovative treatments "tailored to their needs," naming rare disease patients and specialized therapies. ๐Ÿณ. ๐—ง๐—ต๐—ฒ ๐—จ๐—ž ๐˜€๐—ถ๐—ฑ๐—ฒ 2014: DCVax-L receives the UK's first-ever Promising Innovative Medicine designation. Nov 2025: the MHRA's rare therapies paper says large randomized trials in small populations can be "unfeasible and potentially unethical." Feb 2026: England's National Cancer Plan gives rare cancers their own chapter and names brain tumours a priority. March 2026: the Rare Cancers Act orders a review of orphan drug rules for cancer. Oct 2026: after the Prime Minister meets a brain cancer patient, the government tells the MHRA to speed up its orphan drug review. ๐Ÿด. ๐—ง๐—ต๐—ฒ ๐—ฝ๐—ฟ๐—ฒ๐—ฐ๐—ฒ๐—ฑ๐—ฒ๐—ป๐˜ Casgevy. The MHRA approved it first, on Nov 16, 2023. Saudi approval was announced 54 days later. ๐Ÿต. ๐—ง๐—ต๐—ฒ ๐˜„๐—ฒ๐—ฒ๐—ธ Same week in London: the MHRA hosts the ICMRA conference on drug development for small patient populations, and the five Access Consortium regulators agree on a secure platform for work-sharing. The MHRA has not ruled yet. But the plant is licensed, the Saudi filer is named, the Saudi door is open, and the two regulators now have a direct line. Remove every product that does not need this agreement. One is left.
#dcvax $nwbo #gbm MHRA - A significant step forward for international Regulatory Collaboration.. linkedin.com/posts/medicinesโ€ฆ investorshub.advfn.com/boardโ€ฆ
2
21
1
68
2,479
Replying to @DrOzCMS
@DrOzCMS @SecKennedy @Siobhain_Mc @MHRAgovuk Please listen to and follow Dr. Caravello!! You will learn what youโ€™re seeking. Heโ€™ll show you the answers you seek for brain cancer (all solid tumors actually)! #DCVax is the way and heโ€™ll explain how!
Replying to @Siobhain_Mc
$NWBO #DCVax #DCVaxForBraelyn #Glioblastoma Siobhain, please put Braelyn Hollensbe and DCVax-L at the centre of this debate. Sharon Hodgson raised Braelynโ€™s case in the Commons on 4 November. ๐—ฃ๐—ต๐—ฎ๐˜€๐—ฒ ๐—œ๐—œ๐—œ ๐—ถ๐˜€ ๐—ฐ๐—ผ๐—บ๐—ฝ๐—น๐—ฒ๐˜๐—ฒ. ๐—ง๐—ต๐—ฒ ๐—ฟ๐—ฒ๐˜€๐˜‚๐—น๐˜๐˜€ ๐—ฎ๐—ฟ๐—ฒ ๐—ฝ๐˜‚๐—ฏ๐—น๐—ถ๐˜€๐—ต๐—ฒ๐—ฑ. DCVax-L has completed a 331-patient phase III trial. Its published survival analysis reported five-year survival of 13.0% versus 5.7% in external controls. Subsequent patient-level propensity-score matching, presented at BNOS, reported median survival advantages of 3.4โ€“6.3 months. A separate weighting method produced directionally consistent findings. INSIGhT independently tested the external-control approach against known randomized results. Carefully matched external controls reproduced the absence of survival benefit for three experimental drugs. That gives the method a concrete benchmark in glioblastoma. ๐—ก๐—›๐—ฆ ๐—•๐—น๐—ผ๐—ผ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐—ง๐—ฟ๐—ฎ๐—ป๐˜€๐—ฝ๐—น๐—ฎ๐—ป๐˜ ๐—ถ๐˜€ ๐—ฎ๐—น๐—ฟ๐—ฒ๐—ฎ๐—ฑ๐˜† ๐˜€๐˜‚๐—ฝ๐—ฝ๐—ผ๐—ฟ๐˜๐—ถ๐—ป๐—ด ๐—ฝ๐—ฟ๐—ผ๐—ฑ๐˜‚๐—ฐ๐˜๐—ถ๐—ผ๐—ป. On 8 October, NHS Blood and Transplant announced a collaboration with Northwest Biotherapeutics and Advent BioServices to support DCVax-L production, initially involving Leeds and Oxford. This is a patient-derived treatment: the patientโ€™s own dendritic cells are loaded with material from that patientโ€™s tumor. The phase III publication described treatment as well tolerated. CheckMate 143, 498 and 548 failed to improve survival in glioblastoma. Ipi-Glio failed too. WIN-Glio is a separate phase I study testing ipilimumab before standard treatment. Its recruitment, safety and survival reporting should be transparent. ๐—–๐—ผ๐—บ๐—ฏ๐—ถ๐—ป๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฑ๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜ ๐—บ๐˜‚๐˜€๐˜ ๐—ฎ๐—ฑ๐—ฑ๐—ฟ๐—ฒ๐˜€๐˜€ ๐—ถ๐—บ๐—บ๐˜‚๐—ป๐—ฒ ๐—ถ๐—ป๐˜€๐˜๐—ฟ๐˜‚๐—ฐ๐˜๐—ถ๐—ผ๐—ป. Put DCVax-L at the foundation of that work: prepare the cells that teach the immune response, then test the partners that sustain its attack. Dendritic-cell vaccination and checkpoint blockade address complementary parts of the task. The UK marketing application was submitted in December 2023. Northwestโ€™s November 2026 filing still describes the MHRA review as ongoing. What specific issues remain unresolved? Who is responsible for resolving them, and on what timetable? What patient-access arrangements are being prepared alongside the review? ๐—ฃ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜๐˜€ ๐—ฐ๐—ฎ๐—ป๐—ป๐—ผ๐˜ ๐˜€๐—ฝ๐—ฒ๐—ป๐—ฑ ๐˜๐—ต๐—ฒ ๐—ฟ๐—ฒ๐˜€๐˜ ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ๐—ถ๐—ฟ ๐—น๐—ถ๐˜ƒ๐—ฒ๐˜€ ๐˜„๐—ฎ๐—ถ๐˜๐—ถ๐—ป๐—ด ๐—ณ๐—ผ๐—ฟ ๐—ฎ๐—ป๐˜€๐˜„๐—ฒ๐—ฟ๐˜€. EVIDENCE DCVax-L phase III results and safety: jamanetwork.com/journals/jamโ€ฆ BNOS propensity-score matching and weighting analyses: nwbio.com/wp-content/uploadsโ€ฆ INSIGhT external-control reanalysis: pubmed.ncbi.nlm.nih.gov/4217โ€ฆ NHSBT production collaboration: nwbio.com/northwest-biotheraโ€ฆ Current company filing on the MHRA review: sec.gov/Archives/edgar/data/โ€ฆ CheckMate 143: pmc.ncbi.nlm.nih.gov/articleโ€ฆ CheckMate 498: pmc.ncbi.nlm.nih.gov/articleโ€ฆ CheckMate 548: pmc.ncbi.nlm.nih.gov/articleโ€ฆ Ipi-Glio: pubmed.ncbi.nlm.nih.gov/4080โ€ฆ WIN-Glio registration: clinicaltrials.gov/study/NCTโ€ฆ UCLA combination research using its academic ATL-DC vaccine, Hiltonol and pembrolizumab: clinicaltrials.gov/study/NCTโ€ฆ Braelynโ€™s case raised in Parliament: hansard.parliament.uk/pdf/coโ€ฆ
1
8
40
318
@Siobhain_Mc Amanda @HollensbeAmanda listened to him and now look at how well Braelyn @HollensbeBrae is thriving!!
3
29
#NWBO's DCVax-L has been saving lives for 20 years and still no approval?!?!?!?! WTF!!!!
$NWBO @NorthwestBioโ€™s DCVax platform saved Brad Silverโ€™s life. More than 20 years ago he was diagnosed with glioblastoma and given 2 months to live. Then he met Dr Linda Liau and Dr. Robert M. Prins at @UCLAStrokeNSG and was accepted into a clinical trial for DCVax. DCVax is a non-toxic promising Phase 3 treatment for glioblastoma and all solid tumors. Thanks @peter_brit for the find.
1
11
56
735
Replying to @JG_Nuke
Michael Intrator $CRWV CEO dumps ~ $1B in stock yet Wall Street and Silicon Valley calls them "visionaries" or "pioneers." Meanwhile โ€‹a biotech CEO like $NWBO Linda Powers holds hundreds of millions of locked-up shares, lends her own cash to the company at 0% interest, yet @adamfeuerstein villainizes her after actually saving cancer patients. โ€‹Watch what insiders DO with their own money not what some talking head crank says on social media or CNBC.
1
7
39
894
Standard of Care does NOT do this for GBM patients today! This life-saving treatment needs to be approved NOW!! Patients canโ€™t wait!! @DrOzCMS @FDADrugs @MHRAgovuk @SecKennedy $NWBO #DCVax
โค๏ธ๐Ÿ™ ANOTHER MRI. ANOTHER ANSWERED PRAYER! NO EVIDENCE OF DISEASE!!! ๐ŸŽ‰โค๏ธ Today, Braelyn had another brain MRI, and I am absolutely OVERJOYED to share that it once again showed NO EVIDENCE OF DISEASE! NO CHANGE from her August MRI! And just FOUR DAYS AGO, on Friday, November 6, Braelyn received her 5th DCVax-L treatment in London! ๐Ÿ‡ฌ๐Ÿ‡ง I cannot begin to describe the emotions. After more than three years of fighting this devastating brain cancer, three major brain tumor surgeries, radiation, countless treatments, and more fear than I ever imagined a mother could endure, we are now celebrating another MRI showing NO EVIDENCE OF DISEASE! I wish I could tell you that the scanxiety gets easier. But it doesnโ€™t. At least not for me. Every MRI brings back the memories of devastating scans, heartbreaking news, and the terrifying uncertainty of what might come next. I still find myself holding my breath, praying desperately for those words. And today, we heard them again. NO EVIDENCE OF DISEASE. โค๏ธ๐Ÿ™ My heart is overflowing with gratitude. To every single person who has prayed for Braelyn, supported our family, donated to help make her treatments possible, shared her story, or simply sent us words of encouragementโ€”THANK YOU! You have helped carry us through the darkest days of our lives, and you are now helping us celebrate some of the brightest. And to Northwest Biotherapeutics ($NWBO), the brilliant Dr. Linda Liau at UCLA, and the extraordinary Professor Keyoumars Ashkan at Kingโ€™s College Hospitalโ€”there are simply no words adequate to express our gratitude. Thank you for your dedication, your compassion, and your determination to bring new hope to patients facing this devastating disease. Braelyn is 19 years old. Sheโ€™s attending college. Sheโ€™s dreaming about her future. And today, once again, her MRI shows NO EVIDENCE OF DISEASE! GOD IS GOOD! โค๏ธ๐Ÿ™ #DCVax #BrainCancer #BraelynsFight #NoEvidenceOfDisease #DCvaxForBraelyn
8
53
740
$NWBO @LessIsM14781097 uclahealth.org/news/article/โ€ฆ DUD, did you see what Linda Liau had to say about DCVax-L that validates everything Iโ€™ve said about ATL-DC the last 4 years and make your โ€œemail correspondenceโ€ a make believe happening in Never Neverland? โ€œThe vaccine, an autologous tumor lysate-pulsed dendritic cell vaccination (ATL-DC) known as DCVax-Lโ€ Ouch. Adam Feuerstein lied, you lied, exwannabe lied and Jerry Campbell stickied the lie. Thatโ€™s how LieHub rolls! This is from me. The new crypto currency, Judas Coin. A commemorative token to remember all the bullshit you lot brought to the game during the last 4 years.
Replying to @FlemmingBruce
Dud, did you see that Dr. Prins had nothing to say about NWBO, validates (again) the e-mail exchange we had many years ago. Past performance can be indicative of future results. Independent research and analysis could possibly prevent the financial situation you're in (again).
3
14
81
3,658
The 19.3 vs 16.5 median is the least interesting number in the dataset. Focusing only on that and calling it a press release ignores what was published in JAMA Oncology. 5-year survival was 13.0% with DCVax-L vs 5.7% in matched external controls. Recurrent disease was 13.2 vs 7.8 months (HR 0.58). These are peer-reviewed Phase 3 results, not a company release. Individual patient-level propensity score matching against external controls from multiple trials later showed larger advantages than the original 2.8-month median difference on the order of 3.4 to 6.3 months depending on the comparator. And no, this is not built on โ€œone mechanic from Kent.โ€ Jeannine Walston (first patient on the DCVax platform at UCLA, diagnosed 1998) is now approaching three decades. Other long-term GBM survivors associated with Liauโ€™s work include: โ€ขJennifer, 25+ years โ€ขBrad, 22+ years โ€ขElijah, 18+ years โ€ขGallia, 14+ years โ€ขJamil, 13+ years
1
1
8
102
โค๏ธ THIS is why we keep fighting! Andrew, I cannot thank you enough for the extraordinary time, research, and dedication youโ€™ve poured into this proposal. You understand something that families like ours know all too well: Accessing a promising treatment is only half the battle. Being able to CONTINUE that treatment is just as important. Braelyn is 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE. Yet we must continue traveling across the Atlantic and raising tens of thousands of dollars for each DCVax treatment. No family fighting for their childโ€™s life should have to face these barriers. To see Braelynโ€™s story helping inspire meaningful proposals to the FDAโ€”and being shared in the British Parliament in the SAME WEEKโ€”is almost surreal! My deepest hope is that the doors weโ€™re fighting to open for Braelyn will remain open for every patient who comes after her. Thank you, Andrew, for standing with us and turning compassion into action. โค๏ธ๐Ÿ™๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ฌ๐Ÿ‡ง Please read Andrewโ€™s proposal and add your voice to the FDAโ€™s public comment process!
$NWBO #DCVax #DCVaxForBraelyn #RareCancer #RareDisease #Immunotherapy #PatientAdvocacy #GBM ๐Ÿงฌ ๐—ง๐—ต๐—ฒ ๐——๐—–๐—ฉ๐—ฎ๐˜… ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ผ๐˜€๐—ฎ๐—น ๐—ถ๐˜€ ๐—ป๐—ผ๐˜„ ๐—ผ๐—ป ๐˜๐—ต๐—ฒ ๐—™๐——๐—” ๐—ฟ๐—ฒ๐—ฐ๐—ผ๐—ฟ๐—ฑ. A 19-year-old was in college when she began DCVax-L in London. Treatment had started. Her family was still raising money for the next dose. Her mother's account stayed with me. Underneath it is one question: ๐—›๐—ผ๐˜„ ๐—ฑ๐—ผ๐—ฒ๐˜€ ๐—ฎ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜ ๐˜€๐˜๐—ฎ๐—ฟ๐˜ ๐˜๐—ฟ๐—ฒ๐—ฎ๐˜๐—บ๐—ฒ๐—ป๐˜ ๐—ฎ๐—ป๐—ฑ ๐—ธ๐—ฒ๐—ฒ๐—ฝ ๐—ด๐—ฒ๐˜๐˜๐—ถ๐—ป๐—ด ๐—ถ๐˜? On November 6, my 21-page proposal became part of the public record for the FDA's Rare Disease Framework Initiative. I filed it as a physician and patient advocate, independent of Northwest Biotherapeutics. Both treatments start with the patient's own dendritic cells, the cells that teach T cells what to recognize. DCVax-L introduces them to material from the patient's tumor in the lab. DCVax-Direct is injected into a lesion so they meet the tumor there. Same cells, two ways to show them the target. Rare cancers come with no playbook for getting a treatment like this and keeping it. The proposal asks FDA to write one, using ๐——๐—–๐—ฉ๐—ฎ๐˜…-๐—Ÿ ๐—ฎ๐—ป๐—ฑ ๐——๐—–๐—ฉ๐—ฎ๐˜…-๐——๐—ถ๐—ฟ๐—ฒ๐—ฐ๐˜ as the working example. ๐—ง๐—ต๐—ฒ ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ผ๐˜€๐—ฎ๐—น ๐—ฎ๐˜€๐—ธ๐˜€ ๐—™๐——๐—” ๐—ณ๐—ผ๐—ฟ ๐˜๐—ต๐—ฟ๐—ฒ๐—ฒ ๐˜๐—ต๐—ถ๐—ป๐—ด๐˜€, ๐—ถ๐—ป ๐˜„๐—ฟ๐—ถ๐˜๐—ถ๐—ป๐—ด: 1. What the evidence supports for each treatment. 2. Who must arrange to preserve tumor tissue before surgery. 3. Who is responsible for supply and follow-up, so a family knows whom to call when the next dose is due. Plain answers, on paper, so the next family is not guessing. ๐Ÿ“„ ๐—ฅ๐—ฒ๐—ฎ๐—ฑ ๐˜๐—ต๐—ฒ ๐—ฝ๐˜‚๐—ฏ๐—น๐—ถ๐—ฐ ๐—ณ๐—ถ๐—น๐—ถ๐—ป๐—ด regulations.gov/comment/FDA-โ€ฆ ๐Ÿ“– ๐—ข๐—ฝ๐—ฒ๐—ป ๐˜๐—ต๐—ฒ ๐—ณ๐˜‚๐—น๐—น ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ผ๐˜€๐—ฎ๐—น ยท ๐Ÿฎ๐Ÿญ ๐—ฝ๐—ฎ๐—ด๐—ฒ๐˜€ ยท ๐Ÿฑ๐Ÿฎ ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ๐˜€ mirrulations.s3.amazonaws.coโ€ฆ ๐—ช๐—ต๐—ฎ๐˜ ๐—ฑ๐—ผ ๐˜†๐—ผ๐˜‚ ๐˜„๐—ถ๐˜€๐—ต ๐˜€๐—ผ๐—บ๐—ฒ๐—ผ๐—ป๐—ฒ ๐—ต๐—ฎ๐—ฑ ๐˜๐—ผ๐—น๐—ฑ ๐˜†๐—ผ๐˜‚๐—ฟ ๐—ณ๐—ฎ๐—บ๐—ถ๐—น๐˜† ๐˜€๐—ผ๐—ผ๐—ป๐—ฒ๐—ฟ? FDA is taking public comments through ๐——๐—ฒ๐—ฐ๐—ฒ๐—บ๐—ฏ๐—ฒ๐—ฟ ๐Ÿญ๐Ÿญ, ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ. You do not need to be a doctor or a lawyer. A few sentences in your own words count: the barrier your family hit, what it cost the person you love, and the one thing you want FDA to change. To stand behind this proposal, cite ๐—™๐——๐—”-๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ-๐—ก-๐Ÿญ๐Ÿฎ๐Ÿฎ๐Ÿญ๐Ÿฐ-๐Ÿฌ๐Ÿฌ๐Ÿฏ๐Ÿต. No family should be raising money for the next dose while their child is mid-treatment. ๐—ง๐—ฒ๐—น๐—น ๐—™๐——๐—”. โœ๏ธ ๐—”๐—ฑ๐—ฑ ๐˜†๐—ผ๐˜‚๐—ฟ ๐˜ƒ๐—ผ๐—ถ๐—ฐ๐—ฒ ๐˜๐—ผ ๐˜๐—ต๐—ฒ ๐—™๐——๐—” ๐—ฑ๐—ผ๐—ฐ๐—ธ๐—ฒ๐˜ regulations.gov/commenton/FDโ€ฆ ๐ŸŽฅ ๐—ง๐—ต๐—ฎ๐˜ ๐Ÿญ๐Ÿต-๐˜†๐—ฒ๐—ฎ๐—ฟ-๐—ผ๐—น๐—ฑ ๐—ต๐—ฎ๐˜€ ๐—ฎ ๐—ป๐—ฎ๐—บ๐—ฒ. On Wednesday, Braelyn Hollensbe sat in the gallery of the House of Commons while an MP asked the Government to help get this treatment into widespread use, and the First Secretary of State replied that the Prime Minister has taken a personal interest. One Parliament has asked the question out loud. The FDA docket is where the rest of us ask it. @FDA @ReaganUdall @RareDiseases @NBTStweets @HollensbeAmanda @mfhugo1 @ThomasOwenMcCa1 @peter_brit @greta @DrOzCMS @DrOz @MelDMann @AlMusella @MHRAgovuk
5
47
1
182
3,345
$NWBO #DCVax #DCVaxForBraelyn #RareCancer #RareDisease #Immunotherapy #PatientAdvocacy #GBM ๐Ÿงฌ ๐—ง๐—ต๐—ฒ ๐——๐—–๐—ฉ๐—ฎ๐˜… ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ผ๐˜€๐—ฎ๐—น ๐—ถ๐˜€ ๐—ป๐—ผ๐˜„ ๐—ผ๐—ป ๐˜๐—ต๐—ฒ ๐—™๐——๐—” ๐—ฟ๐—ฒ๐—ฐ๐—ผ๐—ฟ๐—ฑ. A 19-year-old was in college when she began DCVax-L in London. Treatment had started. Her family was still raising money for the next dose. Her mother's account stayed with me. Underneath it is one question: ๐—›๐—ผ๐˜„ ๐—ฑ๐—ผ๐—ฒ๐˜€ ๐—ฎ ๐—ฝ๐—ฎ๐˜๐—ถ๐—ฒ๐—ป๐˜ ๐˜€๐˜๐—ฎ๐—ฟ๐˜ ๐˜๐—ฟ๐—ฒ๐—ฎ๐˜๐—บ๐—ฒ๐—ป๐˜ ๐—ฎ๐—ป๐—ฑ ๐—ธ๐—ฒ๐—ฒ๐—ฝ ๐—ด๐—ฒ๐˜๐˜๐—ถ๐—ป๐—ด ๐—ถ๐˜? On November 6, my 21-page proposal became part of the public record for the FDA's Rare Disease Framework Initiative. I filed it as a physician and patient advocate, independent of Northwest Biotherapeutics. Both treatments start with the patient's own dendritic cells, the cells that teach T cells what to recognize. DCVax-L introduces them to material from the patient's tumor in the lab. DCVax-Direct is injected into a lesion so they meet the tumor there. Same cells, two ways to show them the target. Rare cancers come with no playbook for getting a treatment like this and keeping it. The proposal asks FDA to write one, using ๐——๐—–๐—ฉ๐—ฎ๐˜…-๐—Ÿ ๐—ฎ๐—ป๐—ฑ ๐——๐—–๐—ฉ๐—ฎ๐˜…-๐——๐—ถ๐—ฟ๐—ฒ๐—ฐ๐˜ as the working example. ๐—ง๐—ต๐—ฒ ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ผ๐˜€๐—ฎ๐—น ๐—ฎ๐˜€๐—ธ๐˜€ ๐—™๐——๐—” ๐—ณ๐—ผ๐—ฟ ๐˜๐—ต๐—ฟ๐—ฒ๐—ฒ ๐˜๐—ต๐—ถ๐—ป๐—ด๐˜€, ๐—ถ๐—ป ๐˜„๐—ฟ๐—ถ๐˜๐—ถ๐—ป๐—ด: 1. What the evidence supports for each treatment. 2. Who must arrange to preserve tumor tissue before surgery. 3. Who is responsible for supply and follow-up, so a family knows whom to call when the next dose is due. Plain answers, on paper, so the next family is not guessing. ๐Ÿ“„ ๐—ฅ๐—ฒ๐—ฎ๐—ฑ ๐˜๐—ต๐—ฒ ๐—ฝ๐˜‚๐—ฏ๐—น๐—ถ๐—ฐ ๐—ณ๐—ถ๐—น๐—ถ๐—ป๐—ด regulations.gov/comment/FDA-โ€ฆ ๐Ÿ“– ๐—ข๐—ฝ๐—ฒ๐—ป ๐˜๐—ต๐—ฒ ๐—ณ๐˜‚๐—น๐—น ๐—ฝ๐—ฟ๐—ผ๐—ฝ๐—ผ๐˜€๐—ฎ๐—น ยท ๐Ÿฎ๐Ÿญ ๐—ฝ๐—ฎ๐—ด๐—ฒ๐˜€ ยท ๐Ÿฑ๐Ÿฎ ๐˜€๐—ผ๐˜‚๐—ฟ๐—ฐ๐—ฒ๐˜€ mirrulations.s3.amazonaws.coโ€ฆ ๐—ช๐—ต๐—ฎ๐˜ ๐—ฑ๐—ผ ๐˜†๐—ผ๐˜‚ ๐˜„๐—ถ๐˜€๐—ต ๐˜€๐—ผ๐—บ๐—ฒ๐—ผ๐—ป๐—ฒ ๐—ต๐—ฎ๐—ฑ ๐˜๐—ผ๐—น๐—ฑ ๐˜†๐—ผ๐˜‚๐—ฟ ๐—ณ๐—ฎ๐—บ๐—ถ๐—น๐˜† ๐˜€๐—ผ๐—ผ๐—ป๐—ฒ๐—ฟ? FDA is taking public comments through ๐——๐—ฒ๐—ฐ๐—ฒ๐—บ๐—ฏ๐—ฒ๐—ฟ ๐Ÿญ๐Ÿญ, ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ. You do not need to be a doctor or a lawyer. A few sentences in your own words count: the barrier your family hit, what it cost the person you love, and the one thing you want FDA to change. To stand behind this proposal, cite ๐—™๐——๐—”-๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ-๐—ก-๐Ÿญ๐Ÿฎ๐Ÿฎ๐Ÿญ๐Ÿฐ-๐Ÿฌ๐Ÿฌ๐Ÿฏ๐Ÿต. No family should be raising money for the next dose while their child is mid-treatment. ๐—ง๐—ฒ๐—น๐—น ๐—™๐——๐—”. โœ๏ธ ๐—”๐—ฑ๐—ฑ ๐˜†๐—ผ๐˜‚๐—ฟ ๐˜ƒ๐—ผ๐—ถ๐—ฐ๐—ฒ ๐˜๐—ผ ๐˜๐—ต๐—ฒ ๐—™๐——๐—” ๐—ฑ๐—ผ๐—ฐ๐—ธ๐—ฒ๐˜ regulations.gov/commenton/FDโ€ฆ ๐ŸŽฅ ๐—ง๐—ต๐—ฎ๐˜ ๐Ÿญ๐Ÿต-๐˜†๐—ฒ๐—ฎ๐—ฟ-๐—ผ๐—น๐—ฑ ๐—ต๐—ฎ๐˜€ ๐—ฎ ๐—ป๐—ฎ๐—บ๐—ฒ. On Wednesday, Braelyn Hollensbe sat in the gallery of the House of Commons while an MP asked the Government to help get this treatment into widespread use, and the First Secretary of State replied that the Prime Minister has taken a personal interest. One Parliament has asked the question out loud. The FDA docket is where the rest of us ask it. @FDA @ReaganUdall @RareDiseases @NBTStweets @HollensbeAmanda @mfhugo1 @ThomasOwenMcCa1 @peter_brit @greta @DrOzCMS @DrOz @MelDMann @AlMusella @MHRAgovuk
6
49
7
193
30,678
IrishMc67 retweeted
Replying to @ablidy
@ablidy @andyburnham $NWBO platform for cancer
What an absolute honor to have been invited to sit in the Speakerโ€™s VIP box. A huge Thank You to Sharon Hodgson, Labour MP for highlighting this very important issue affecting so many people in both of our countries, and beyond. We are grateful for the warm reception and the support of our โ€œcousinsโ€ on the other side of the pond! #DcVaxForBraelyn @DrOzCMS
3
37
600
#Glioblastoma $NWBO #DCVax #Immunotherapy #SITC2026 #SITC26 Mel lived the first one. In 1998 a Phase 1 trial took a terminal leukemia and turned it into a disease people grow old with. #Gleevec works because CML runs on one broken switch, BCR-ABL, and one pill can jam it. The common solid tumors never offered one switch. Each carries its own private set of mutations, and when a drug does find a target the tumor rewires around it. That is why there has never been a Gleevec for the cancers that kill most people. DCVax-L does not chase mutations. The patient's own dendritic cells are loaded with the whole tumor, not a chosen piece of it, and the immune system picks the targets. In newly diagnosed glioblastoma that produced 13% alive at five years (or more) against 5.7% for propensity score matched external controls. A curve with a tail is what immune memory looks like. It happened in the textbook cold tumor. Few T cells ever reach a glioblastoma, which is why checkpoint drugs failed there in three Phase 3 trials. A checkpoint drug releases the brakes on T cells that already exist. In a cold tumor there is nothing to release. Dendritic cells sit one step upstream. They create those T cells, so the vaccine does not need the tumor to be warm. It is how a tumor gets warm. And once it is warm, the checkpoint drug that failed alone finally has something to work with. Dr. Liau's UCLA group tested the order in recurrent glioblastoma and reported the result at EANO 2026. In 35 patients, Keytruda before the vaccine meant a median survival of 271 days. Keytruda after the vaccine meant 555 days, and the risk of death fell by two thirds. Tumor and blood showed why: more T cells in the tumor and more interferon and granzyme when the vaccine came first. Same two drugs, same disease. The order alone doubled survival. The trial proved the platform in glioblastoma. The platform never cared which tumor the lysate came from, and the sequence does not care either. ๐—ง๐—ต๐—ฎ๐˜ ๐—ถ๐˜€ ๐˜๐—ต๐—ฒ ๐˜๐—ฟ๐˜‚๐—ฒ ๐—š๐—น๐—ฒ๐—ฒ๐˜ƒ๐—ฒ๐—ฐ ๐—บ๐—ผ๐—บ๐—ฒ๐—ป๐˜, ๐—ฎ๐—ป๐—ฑ ๐˜๐—ต๐—ถ๐˜€ ๐˜๐—ถ๐—บ๐—ฒ ๐—ถ๐˜ ๐—ถ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—ฒ๐˜ƒ๐—ฒ๐—ฟ๐˜† ๐˜€๐—ผ๐—น๐—ถ๐—ฑ ๐˜๐˜‚๐—บ๐—ผ๐—ฟ. #DCVaxForBraelyn @HollensbeAmanda @ThomasOwenMcCa1 @mfhugo1 @MHRAgovuk @FDA @DrOzCMS @greta @kshaughnessy2 @peterjkostis @Siobhain_Mc @parkerici
Glioblastoma rarely gives good news. The peer-reviewed phase 3 DCVax-L trial showed a statistically significant overall survival benefit in both newly diagnosed and recurrent disease. Brain Tumour Research called the results astonishing. Any validated survival gain matters for patients and families facing this cancer.
1
26
2
91
24,711
#SITC26 #SITC2026 $NWBO #DCVaxForBraelyn #CancerVaccines #RareCancers ๐“๐ก๐ž ๐“๐š๐ซ๐ ๐ž๐ญ ๐ˆ๐ฌ ๐Ž๐ง๐ฅ๐ฒ ๐ญ๐ก๐ž ๐’๐ญ๐š๐ซ๐ญ What an ovarian-cancer vaccine trial reveals about immune escape, and why #DCVax makes the presenter part of the treatment. A cancer vaccine can begin with a precise picture of a tumor. Durable control requires the immune response to remain effective as the tumor changes what it produces, displays and needs to survive. The NeoVax trial reported by Sellars and colleagues investigated an aggressive ovarian-cancer category called high-grade epithelial ovarian cancer. It tested a therapeutic vaccine, meaning a treatment for people already diagnosed with cancer. Nine vaccinated patients were at their first recurrence and one was newly diagnosed, following platinum-based chemotherapy.ยน Researchers selected abnormal protein sequences from each patient's tumor and manufactured matching fragments, called peptides. NeoVax combined them with the immune stimulant poly-ICLC. Nivolumab, which releases an immune brake, began later. Ten patients received vaccine; blood markers of tumor burden showed patterns consistent with activity in six.ยน That is meaningful activity. It also leaves the question that matters most to the patient: can the response keep controlling the cancer as the cancer changes? Dendritic cells occupy a crucial position in that question. They take up material, process it and display fragments to T cells, immune cells that coordinate or carry out an attack. Their accompanying signals help determine what kind of response develops. The antigen supplies something to recognize; the presenting cell helps establish what the receiving cells will do about it.ยฒ ๐“๐ก๐ž๐ซ๐ž ๐š๐ซ๐ž ๐ญ๐ฐ๐จ ๐๐ข๐ฌ๐ฉ๐ฅ๐š๐ฒ๐ฌ ๐ข๐ง ๐ญ๐ก๐ข๐ฌ ๐ฌ๐ญ๐จ๐ซ๐ฒ. The dendritic cell displays a fragment to teach a T cell. The cancer cell must display a compatible target for that trained killer T cell to recognize it. A successful first encounter does not guarantee a successful second one. The ovarian trial exposed several escape routes. Some tumors had lost genes encoding HLA, the molecules that display targets on cell surfaces. Recurrence samples lost selected vaccine-target mutations. In another patient, an alteration in JAK1 impaired the tumor's response to interferon, an immune signal that can increase antigen display. Restoring JAK1 in laboratory-grown tumor models restored recognition by vaccine-specific T cells.ยน That is a failure of access to the target. An immune cell can be capable of recognizing a particular display while the cancer no longer makes that display. Personalizing a target to the patient's genetic background does not ensure that the surviving tumor remains visible through it. Nivolumab blocks an inhibitory receptor on T cells. Blocking that receptor does not replace a missing tumor gene or restore a lost target. Releasing a brake and making the cancer recognizable are different biological jobs.ยณ Vivek Subbiah and colleagues' new review examines cancer plasticity, the ability of cancer cells to change their identity and behavior. Some transformed lung cancers retain the mutation that originally guided treatment while changing their protein expression and losing sensitivity to drugs aimed at that pathway. The DNA finding remains real while the tumor's biology has moved on. The review also describes changes in antigen display and the immune surroundings during transformation. For vaccination, the implication is temporal: recognition must remain matched to the cancer that exists now.โด This is where the DCVax approach changes the design of the intervention. The treatment includes the patient's prepared dendritic cells, bringing antigen presentation itself into the product. DCVax-L brings those cells together with material from the patient's removed tumor outside the body. The material is processed into tumor lysate, a mixture of cellular contents that provides an antigen source for the dendritic cells.โต DCVax-Direct takes a different route. Cells collected from the patient's blood are developed and partially activated outside the body, then injected into an accessible tumor. They are intended to acquire tumor material there and help initiate an immune response.โถ ๐ƒ๐ž๐ง๐๐ซ๐ข๐ญ๐ข๐œ ๐œ๐ž๐ฅ๐ฅ๐ฌ ๐๐จ ๐›๐ข๐จ๐ข๐ง๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐œ๐ฌ ๐Ÿ๐จ๐ซ ๐š ๐ฅ๐ข๐ฏ๐ข๐ง๐ . They process complex tumor material into fragments that can be displayed through the patient's own presentation molecules. Their condition also shapes the signals delivered with those fragments. NeoVax calls on this machinery inside the patient. DCVax makes prepared dendritic cells part of the medicine, allowing the presenter's condition to be shaped and examined before administration. This is the biological substance behind calling dendritic cells instructors. Their work extends beyond holding up a target. A helper T cell can recognize their display and return a licensing signal, strengthening their ability to support cancer-killing T cells. The helper and killer need not arrive simultaneously; the conditioned dendritic cell can connect their encounters across time.โท IL-12 adds another instruction, supporting the coordinated cellular attack called type 1 immunity. Activated T cells can return interferon gamma, prompting dendritic cells to produce IL-12. Tumor experiments have demonstrated the importance of this reciprocal exchange during PD-1 blockade. The response depends on cells supporting one another, not merely on the presence of a recognizable antigen.โธ Preparation can change the outcome of that conversation. In human-cell experiments, researchers presented the same cancer-associated fragment using differently conditioned dendritic cells. Helper-conditioned cells generated stronger measured killing responses and T cells with features associated with immune memory. ๐“๐ก๐ž ๐ญ๐š๐ซ๐ ๐ž๐ญ ๐ฌ๐ญ๐š๐ฒ๐ž๐ ๐ญ๐ก๐ž ๐ฌ๐š๐ฆ๐ž. ๐“๐ก๐ž ๐ข๐ง๐ฌ๐ญ๐ซ๐ฎ๐œ๐ญ๐ข๐จ๐ง ๐œ๐ก๐š๐ง๐ ๐ž๐.โน The material is collected at a moment; the immune response must operate over time. DCVax-L's lysate comes from a particular collection. Direct's repeated injections offer encounters with material present in a lesion at later times.โถ The host response can also broaden beyond its starting targets through epitope spreading, the development of responses to additional antigens. A human melanoma trial combining a different type 1 dendritic-cell vaccine with dasatinib documented responses beyond its vaccine peptides. A starting sample need not be the final boundary of recognition.ยนโฐ DCVax-Direct's phase I trial also examined activity at the tumor site. ๐–๐ข๐ญ๐ก๐จ๐ฎ๐ญ ๐Š๐ž๐ฒ๐ญ๐ซ๐ฎ๐๐š, biopsies showed increased immune-cell infiltration in about 54% of assessed patients across several advanced cancers. The study identified helper and killer T cells and local immune activity. It also found increased PD-L1, an inhibitory signal, in 19 of 25 evaluated tumors.โถ Those observations give checkpoint combinations a specific rationale: address a brake appearing alongside a response. They also make clear that the activity observed with Direct was already present without a checkpoint drug. This continuing response still needs a reachable target. A manufactured dendritic cell does not reconstruct HLA genes deleted from a cancer cell. If one recognition route is lost, control requires an effective remaining route or another way to attack. Broad antigen acquisition, useful instruction and tumor vulnerability have to remain connected. ๐–๐ข๐ญ๐ก๐จ๐ฎ๐ญ ๐š๐ง ๐ž๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ข๐ฏ๐ž ๐ฐ๐š๐ฒ ๐ญ๐จ ๐œ๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐ญ๐ก๐ž ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐ข๐ง๐  ๐œ๐š๐ง๐œ๐ž๐ซ, ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐š๐œ๐ญ๐ข๐ฏ๐š๐ญ๐ข๐จ๐ง ๐œ๐š๐ง๐ง๐จ๐ญ ๐ฉ๐ซ๐จ๐๐ฎ๐œ๐ž ๐š ๐๐ฎ๐ซ๐š๐›๐ฅ๐ž ๐ซ๐ž๐ฌ๐ฉ๐จ๐ง๐ฌ๐ž. Treatment must preserve the cancer's vulnerability, restore it, or overcome its escape through another effective mechanism. ๐๐ž๐ซ๐ฌ๐จ๐ง๐š๐ฅ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐ฆ๐ฎ๐ฌ๐ญ ๐ซ๐ž๐ฆ๐š๐ข๐ง ๐œ๐ฎ๐ซ๐ซ๐ž๐ง๐ญ. A precise description of yesterday's cancer is a starting point. Durability requires an immune response that can keep controlling the cancer that survives today. ๐’๐จ๐ฎ๐ซ๐œ๐ž๐ฌ 1. Sellars and colleagues, Nature Medicine (2026). Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial. Author manuscript and main/extended-data figures reviewed. nature.com/articles/s41591-0โ€ฆ 2. Nobel Prize scientific background: dendritic cells and adaptive immunity. nobelprize.org/prizes/mediciโ€ฆ 3. National Cancer Institute: nivolumab and PD-1 blockade. cancer.gov/publications/dictโ€ฆ 4. Kuburich, Gouda and colleagues; Mani and Subbiah. Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology. Med (online October 13, 2026). Supplied 23-page corrected proof read in full, including all five figures and the reference list. The connections to DCVax are this essay's synthesis. doi.org/10.1016/j.medj.2026.โ€ฆ 5. Liau and colleagues, Journal of Translational Medicine (2018). Cited for DCVax-L preparation using autologous tumor lysate and dendritic cells. pmc.ncbi.nlm.nih.gov/articleโ€ฆ 6. Subbiah and colleagues, Clinical Cancer Research (2018). DCVax-Direct preparation and phase I findings without Keytruda. Published maturation used GM-CSF, killed BCG and interferon gamma, with no added PGE2 listed. pmc.ncbi.nlm.nih.gov/articleโ€ฆ 7. Ridge and colleagues, Nature (1998). Dendritic-cell conditioning as a temporal bridge between helper and killer T cells. pubmed.ncbi.nlm.nih.gov/9624โ€ฆ 8. Garris and colleagues, Immunity (2018). Reciprocal IFN-gamma and IL-12 signaling during anti-PD-1 treatment in tumor models. pubmed.ncbi.nlm.nih.gov/3055โ€ฆ 9. Simon and colleagues, Biological Research (2012). Human dendritic-cell conditioning, cytotoxic responses and memory-associated phenotypes in culture. pubmed.ncbi.nlm.nih.gov/2268โ€ฆ 10. Storkus and colleagues. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. JITC (2021). Cited for human epitope spreading in a distinct DC-vaccine/dasatinib regimen. pubmed.ncbi.nlm.nih.gov/3478โ€ฆ
A phase 1 clinical trial of a personalized NeoVax vaccine showed that treatment was safe and well tolerated, with early evidence of immune and clinical efficacy bit.ly/4imhd5h ๐Ÿ‘‰ In a phase 1 clinical trial, Sellars et al. evaluated the adjuvant use of personalized cancer vaccines in combination with nivolumab in patients with high-grade ovarian cancer treated with standard-of-care platinum-based chemotherapy. Treatment was feasible and well tolerated, with evidence of vaccine-induced T cell responses and antitumor immunity. Immune escape through several mechanisms was also observed. @danaFarber @harvardmed
1
14
3
42
3,668
IrishMc67 retweeted
Replying to @DrOz
@DrOz @RobertKennedyJr @POTUS $NWBO Would be great to see Amanda and Braelyn in the Oval Office next week with President Trump, Dr Oz, RFK Jr, Dr Liau, Dr. Bosch, Dr Boyton, and Linda Powers to bring forward a pathway for Americans to get DCVAX-L and expedite the approval, especially since it appears MHRA and NHS are on the verge of approving with the UK PM stepping in today. We then need to work on getting the basket trials for all solid tumors and DCVAX-L approved and moving forward. The world could use some good news now and a Cancer break-through 20+ years in the making would greatly help MANKIND! Congratulations on your visit to the UK Parliament today Amanda and Braelyn while on your trip to get Braelyns 5th injection of DCVAX. Hoping this is your last visit to the UK for a treatment! Take care Amanda and Braelyn and safe travels! Do Better @FDA Americans depend on you!
What an absolute honor to have been invited to sit in the Speakerโ€™s VIP box. A huge Thank You to Sharon Hodgson, Labour MP for highlighting this very important issue affecting so many people in both of our countries, and beyond. We are grateful for the warm reception and the support of our โ€œcousinsโ€ on the other side of the pond! #DcVaxForBraelyn @DrOzCMS
26
1
94
2,323
Replying to @parkerici
$NWBO #SITC26 #DCVax #DCVaxForBraelyn #CancerVaccines #RareCancers #Glioblastoma @parkerici @sitcancer @DanaFarber @SharonHodgsonMP @MHRAgovuk @HollensbeAmanda ๐—ฃ๐—ต๐—ผ๐—ฒ๐—ป๐—ถ๐˜… ๐—œ๐˜€ ๐——๐—ถ๐˜€๐—ฐ๐˜‚๐˜€๐˜€๐—ถ๐—ป๐—ด ๐—œ๐˜. ๐—ฃ๐—ฎ๐—ฟ๐—น๐—ถ๐—ฎ๐—บ๐—ฒ๐—ป๐˜ ๐—๐˜‚๐˜€๐˜ ๐—”๐˜€๐—ธ๐—ฒ๐—ฑ ๐—™๐—ผ๐—ฟ ๐—œ๐˜. Thirty-two sessions on cancer vaccines open in Phoenix today. Congratulations to Catherine J. Wu on the Smalley Award. The field has never been more convinced that the immune system can be taught. This morning, an ocean away, the House of Commons was looking at a patient it already worked for. Braelyn Hollensbe was given three months to live at 16. She is 19, she was in the gallery at Prime Minister's Questions, and her scans show no evidence of disease. Sharon Hodgson MP put the whole problem in three facts. The drug is manufactured in the UK. It is the first treatment in decades shown to extend survival in recurrent glioblastoma. It reaches only a tiny number of patients, by exception. The First Secretary of State welcomed Braelyn and said the Health Secretary will look at this urgently. Here is the distinction the Phoenix program will spend five days circling. A sequencer can list a tumour's mutations. It cannot teach them. Antigen selection and antigen instruction are different contributions, and in a patient whose cancer and treatment have already depleted the immune system, the missing piece is the instructor. ๐——๐—ฒ๐—ป๐—ฑ๐—ฟ๐—ถ๐˜๐—ถ๐—ฐ ๐—ฐ๐—ฒ๐—น๐—น๐˜€ ๐—ฑ๐—ผ ๐—ฏ๐—ถ๐—ผ๐—ถ๐—ป๐—ณ๐—ผ๐—ฟ๐—บ๐—ฎ๐˜๐—ถ๐—ฐ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—ฎ ๐—น๐—ถ๐˜ƒ๐—ถ๐—ป๐—ด. Nobody picked Braelyn's targets. Her own cells read the whole tumour and chose. The marketing application for that vaccine has been with the MHRA for 1,050 days. The science is on stage in Phoenix this week. The patient was in Parliament this morning. The file has been on a regulator's desk since December 2023. Approve it. #DCVaxForBraelyn
12
2
45
3,140